Peripheral T‐cell lymphoma, not otherwise specified (PTCL_NOS) corresponds to about one fourth of mature T‐cell tumors, which overall represent 10–12% of all lymphoid malignancies. This category comprises all T‐cell neoplasms, which do not correspond to any of the distinct entities listed in the WHO (World Health Organization) Classification of Tumours of Haematopoietic and Lymphoid Tissues. In spite of the extreme variability of morphologic features and phenotypic profiles, gene expression profiling (GEP) studies have shown a signature that is distinct from that of all remaining PTCLs. GEP has also allowed the identification of subtypes provided with prognostic relevance. Conversely to GEP, next‐generation sequencing (NGS) has so far been applied to a limited number of cases, providing some hints to better understand the pathobiology of PTCL_NOS. Although several pieces of information have emerged from pathological studies, PTCL_NOS still remains a tumor with a dismal prognosis. The usage of CHOEP (cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide) followed by autologous stem cell transplantation may represent the best option, by curing about 50% of the patients whom such an approach can be applied to. Many new drugs have been proposed without achieving the expected results. Thus, the optimal treatment of PTCL_NOS remains unidentified.

Peripheral t‐cell lymphoma, not otherwise specified : Clinical manifestations, diagnosis, and future treatment / S.A. Pileri, V. Tabanelli, S. Fiori, A. Calleri, F. Melle, G. Motta, D. Lorenzini, C. Tarella, E. Derenzini. - In: CANCERS. - ISSN 2072-6694. - 13:18(2021), pp. 4535.1-4535.14. [10.3390/cancers13184535]

Peripheral t‐cell lymphoma, not otherwise specified : Clinical manifestations, diagnosis, and future treatment

D. Lorenzini;C. Tarella;E. Derenzini
2021

Abstract

Peripheral T‐cell lymphoma, not otherwise specified (PTCL_NOS) corresponds to about one fourth of mature T‐cell tumors, which overall represent 10–12% of all lymphoid malignancies. This category comprises all T‐cell neoplasms, which do not correspond to any of the distinct entities listed in the WHO (World Health Organization) Classification of Tumours of Haematopoietic and Lymphoid Tissues. In spite of the extreme variability of morphologic features and phenotypic profiles, gene expression profiling (GEP) studies have shown a signature that is distinct from that of all remaining PTCLs. GEP has also allowed the identification of subtypes provided with prognostic relevance. Conversely to GEP, next‐generation sequencing (NGS) has so far been applied to a limited number of cases, providing some hints to better understand the pathobiology of PTCL_NOS. Although several pieces of information have emerged from pathological studies, PTCL_NOS still remains a tumor with a dismal prognosis. The usage of CHOEP (cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide) followed by autologous stem cell transplantation may represent the best option, by curing about 50% of the patients whom such an approach can be applied to. Many new drugs have been proposed without achieving the expected results. Thus, the optimal treatment of PTCL_NOS remains unidentified.
Cell morphology; Classification; Diagnosis; Gene expression profiling; Next‐generation sequencing; Not otherwise specified; Peripheral T‐cell lymphoma; Phenotype; Prognosis; Therapy
Settore MED/15 - Malattie del Sangue
Article (author)
File in questo prodotto:
File Dimensione Formato  
cancers-13-04535-v3.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 5.3 MB
Formato Adobe PDF
5.3 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/877542
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact